Activity Overview
This online, on-demand virtual symposium brings together experts in the treatment of presbyopia. The use of topical therapies for presbyopia requires careful consideration of mechanisms of action, durability of effect, and potential risks. In this program, the expert faculty who compare characteristics of approved and emerging topical therapies and provide insights into identifying appropriate patients and providing education to help them optimize their use.
This educational activity is an archive of the live
virtual symposium held on May 2, 2026.
Target Audience
This online educational activity is directed toward optometrists
and other eye care professionals involved in the diagnosis and treatment of
patients with presbyopia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the impact of presbyopia on patient quality of life, including its effects on near-vision tasks, daily activities, and visual independence.
- Outline mechanisms of action for pharmacologic therapies used in the management of presbyopia
- Summarize safety and efficacy data regarding pharmacologic therapies for presbyopia
- Apply patient-specific factors to guide the selection of pharmacologic therapies for presbyopia.
- Implement appropriate baseline screening and follow-up monitoring strategies when prescribing pharmacologic treatments for presbyopia.
Brian Szabo, DO
Cataract, Refractive, and Glaucoma Surgeon
Newsom Eye
Tampa, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Glaukos, Johnson & Johnson Vision, RxSight, Starr Surgical
Nick Bruns, OD, FAAO
Optometrist
Director of Practice Development
Summit Eye Care of Wisconsin
Milwaukee, WI
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alcon, BL Pharma, Glaukos, Harrow, LENSAR, Nordic, Orasis, RxSight, STAAR Surgical; Speakers Bureau: Alcon, Glaukos, Nordic, Orasis, RxSight, STAAR
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the
information presented and apply their own clinical judgment when considering
patient care decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here